Cargando…

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo

PURPOSE: The prognosis of patients with multiple myeloma (MM) is still dismal despite recent improvements achieved by introducing new therapeutic agents. However, there remains an urgent need for progress in myeloma drug development. We here show that novel marine-derived compounds can exert potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steiner, Normann, Ribatti, Domenico, Willenbacher, Wolfgang, Jöhrer, Karin, Kern, Johann, Marinaccio, Christian, Aracil, Miguel, García-Fernández, Luis F., Gastl, Guenther, Untergasser, Gerold, Gunsilius, Eberhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480745/ https://www.ncbi.nlm.nih.gov/pubmed/25860931

Ejemplares similares

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo
por: Kern, Johann, et al.
Publicado: (2009)

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
por: Thangavadivel, Shanmugapriya, et al.
Publicado: (2016)

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies
por: Pircher, Andreas, et al.
Publicado: (2016)

Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry
por: Steurer, Michael, et al.
Publicado: (2008)

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets
por: Steiner, Normann, et al.
Publicado: (2018)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia
por: Willenbacher, Ella, et al.
Publicado: (2019)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
por: Martowicz, Agnieszka, et al.
Publicado: (2012)

Adenoviral-Mediated Endothelial Precursor Cell Delivery of Soluble CD115 Suppresses Human Prostate Cancer Xenograft Growth in Mice
por: Lucas, Trevor, et al.
Publicado: (2009)

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
por: Steiner, Normann, et al.
Publicado: (2023)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth
por: Martowicz, Agnieszka, et al.
Publicado: (2013)

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
por: Seeber, Andreas, et al.
Publicado: (2016)

Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
por: Steiner, Normann, et al.
Publicado: (2016)

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
por: Zelle-Rieser, Claudia, et al.
Publicado: (2016)

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report
por: Gauckler, Philipp, et al.
Publicado: (2020)

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia‐variant
por: Locher, Maurus, et al.
Publicado: (2020)

Platelets and VEGF blood levels in cancer patients
por: Gunsilius, E, et al.
Publicado: (1999)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Multiple Myeloma Inhibitory Activity of Plant Natural Products
por: Jöhrer, Karin, et al.
Publicado: (2021)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Dickkopf-3 As a New Potential Marker for Neoangiogenesis in Colorectal Cancer: Expression in Cancer Tissue and Adjacent Non-Cancerous Tissue
por: Zitt, Matthias, et al.
Publicado: (2008)

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Structure-Guided Identification of Black Cohosh (Actaea racemosa) Triterpenoids with In Vitro Activity against Multiple Myeloma
por: Jöhrer, Karin, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

New Insights in Anti-Angiogenesis in Multiple Myeloma
por: Ribatti, Domenico, et al.
Publicado: (2018)

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury
por: Steiner, N., et al.
Publicado: (2020)

Flavones, Flavonols, Lignans, and Caffeic Acid Derivatives from Dracocephalum moldavica and Their In Vitro Effects on Multiple Myeloma and Acute Myeloid Leukemia
por: Jöhrer, Karin, et al.
Publicado: (2022)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4a81qab9i5cet3gpgteb748d91